6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells

Size: px
Start display at page:

Download "6/20/2014. PART I: Plasma Cell Myeloma. Plasma Cells"

Transcription

1 MULTIPLE MYELOMA: THE TESTING, VALIDATION AND IMPLEMENTATION OF CELL SEPARATION TECHNOLOGY FOR IMPROVED PATIENT CARE Elizabeth Harper CG(ASCP), Binh Vo CG(ASCP), Joey Pena CG(ASCP), Denise Lovshe CG(ASCP), Dr. Gary Lu, Dr. Xinyan Lu PART I: Plasma Cell Myeloma The major disease of plasma cell neoplasms Results from the expansion of a clone of immunoglobulin (Ig)-secreting, heavy-chain classswitched, terminally differentiated B cell (plasma cell) Typically secrets a monoclonal immunoglobulin called paraprotein or M-protein The 2 nd most prevalent hematologic neoplasm worldwide 4.3/100,000; 15,000 cases/year in USA; twice as common in blacks Clonal plasma cell expansion Plasma Cells Abundant blue cytoplasm Pale perinuclear zone Round eccentric nucleus, spoke wheel or clock face chromatin without nucleoli May present with multiple nuclei 1

2 Bone Marrow Evaluation Plasma cell count: >30% in BM (if <30%, tumoral mass of plasma cells displacing normal BM elements) Usually occur in interstitial clusters, focal nodules or diffuse sheets Early stage: interstitial and focal Advanced stages: diffuse and or extra-medullary involvement Plasmablastic morphology as a prognostic factor: Immaturity and pleomorphism are reliable indicators of malignant plasma cells A higher percentage of BM plasma cells and higher plasma cell labeling index higher proliferation rate Significant lower response rate Other Markers Elevated β-microglobulin Increased serum calcium Urine protein Bone lesion Immunohistochemistry (IHC) Staining Useful in quantifying plasma cells on biopsy Useful in confirming a monoclonal plasma cell proliferation CD138 stain: useful for quantifying plasma cells, and clonality can usually be established with stains for Kappa and Lambda light chains Useful in distinguishing myeloma from other neoplasms 2

3 Flow Cytometry Analysis Diagnostic markers CD138 expression, CD38 strong expression, and absence to dim CD45 Prognostic markers CD56 higher incidence of extramedullary disease Higher β2-microglobulin Plasmablastic morphology CD44v9: poor prognosis CD20: more aggressive MM subtype, shorter survival CD27: significantly higher in MM remission The Common 4 Cytogenomic Pathways For Myeloma GERMINAL CENTER B-CELL MGUS Aneuploidy (Chromosome gains) IGH/CCND1 XT TP53 hypodiploid, RAS, p18ink4c, others Smoldering Myeloma IGH rearrangements Medullar Myeloma -13/del(13q) Extramedullar Myeloma IGH/FGFR3 Chromosome 1 rearrangements c-myc PCL Aneuploidy Pathway Almost 100% by DNA content analysis by flow cytometry Most are primary Hyperdiploidy in most cases Non-hyperdiploidy 3

4 Plasma cell myeloma (PCM) Monoclonal gammopathy of Undetermined significance (MGUS) 1% IGH Pathway In about 45% MM Involves at least 27 different chromosome partners The most common partners (> 2%): 4, 6, 11, 16, and 20 Diverse prognosis depending on partner involved IGH Rearrangement (1) t(11;14)(q13;q32) 15-20%/FISH in MM; 15-30% in MGUS Involving CCND1 Favorable prognosis if without risk markers 4

5 IGH Rearrangement (2) t(4;14)(p16;q32) 15-20% by FISH Involving FGFR3 The most Unfavorable prognosis IGH Rearrangement (3) t(14;16)(q32;q23) 2-10% by FISH Involving MAF Unfavorable prognosis 5

6 IGH Rearrangement (4) t(6;14)(p21;q32) 3-5% by FISH Involving CCND3 Unfavorable prognosis del(13q)/-13 Pathway 40%-50% by FISH Frequently present w/ t(4;14), t(14;16) and +1q scattered along the long arm by acgh Increased frequency with increased plasma cell bone marrow load Unfavorable prognosis 6

7 Plasma Cell Enrichment Use of CD138 Magnetic MicroBeads: Targets CD138 antigen, a transmembrane heparin sulfate proteoglycan macromolecule CD138+ cells include normal and malignant human plasma cells Not expressed on virgin/naïve B cells, memory B cells, T cells, or monocytes Plasma Cell Enrichment Incubation with CD138 Magnetic MicroBeads to target plasma cells After incubation cells suspension is passed through a Column located in the Magnet Separator The Column is removed from Separator and Elution Buffer is used to flush out magnetically labeled (CD 138+) plasma cells CD38 Immunofluorescent Staining CD38 antigen is a transmembrane glycoprotein with enzymatic activity, high expression on plasma cells Incubate cells with CD38-Biotin antibody, followed by a wash and incubation with anti-biotin-fitc antibody 200 cells scored pre- and post- plasma cell enrichment 7

8 CD38 Immunofluorescent Staining Pre-PCE Case 1 Case 2 7.5% 3.2% Post-PCE 42% 89% PC Enrichment Factor PC Enrichment Factor PC count from Aspirate Smear by Morphology assessment Range: 0-63% Median: 2.6% PC % Pre-PCE: 1-18% Post-PCE: 31-93% Enrichment Factor Range: 4-52 Median:

9 PART II: CURRENT PROCESSING ALGORITHMS Bone marrow sample arrives to lab. Separate all charts with Myeloma diagnosis and with FISH order * Take 2 blue falcon tubes and label them with Patient name and MR# * Invert the syringe to mix, then transfer 1ml of bone marrow into one labeled (Patient Name; MR#) blue tube and the remaining bone marrow into a second labeled (Patient Name; MR#)blue tube. BM FISH CULTURE PROCESSING * Add media, order the BM24-X label and set up the routine specimen with the bone marrow in the blue falcon tube. * If there is extra bone marrow after setting up, record as + sign in volume column of the RoboSep log, next to 1ml. ROBOSEP SAMPLE PROCESSING * Add 2 ml s of media to the 1ml of bone marrow and place in Myeloma Specimens canister in tc room fridge. * Record specimen information on log; next day determine the plasma cell count in Clinic Station; located in Pathology folder. 9

10 ROBOSEP SAMPLE PROCESSING * If the plasma cell concentration is between 3-15%, process specimen using RoboSep for plasma cell separation. * Obtain the enriched plasma cells after the RoboSep process. * Remove RoboSep tubes; shake gently to dislodge PC s from sides of tube and refrigerate ROBOSEP SAMPLE PROCESSIING Perform RoboSep Shutdown Procedure Centrifuge plasma cells and harvest according to procedure. (may be performed immediately or up to 1 day post-processing). RoboSep harvester responsible for notifying routine BM harvesters that Biogenix slides are available. MYELOMA FISH ALGORITHM 10

11 PART III: ROBOSEP PROCESSING, SUPPLIES AND QC Isolation of specimens to be RoboSeped (parameters, location of storage) Preparing samples for RoboSep (buffer wash; lysis buffer) Preparing supplies; readying machine Loading the RoboSep and selecting protocols PART III: PROCESSING THE SAMPLE AND LOADING THE ROBOSEP May use any number of stations up to 4 Machine gives quantity of supplies needed as the selection process for each sample continues Machine runs for 53-1:10 minutes depending upon quantity of samples loaded PART III: LOADING THE ROBOSEP 11

12 PART III: LOADING THE ROBOSEP PART III: ROBOSEP SUPPLIES PART III: ROBOSEP QC 12

13 PART IV: ROBOSEP HARVESTING VALIDATION Over 175 Myeloma patient specimens processed Initial processing performed on plasma cell counts ranging from 0-15% Early attempts to achieve optimal cell count has led to much refinement of what to process and the harvesting procedure. PART IV: ROBOSEP HARVEST VALIDATION Harvester drops suspension on BioGenex slides using micropipettor The harvester checks the quality of the slides and determines which patient slides are acceptable The patient with acceptable slides has their slide condition changed from reserve to epc PART V: COMPARISON AND VALIDATION OF FISH PROBES Myeloma Panel CCND1/IGH-XT t(11;14) RB1 (13q14) P53 (17p13.1) CKS1B (1p32.3 & 1q21) 10 samples for each probe 13

14 CCND1/IGH-XT PROBE ROBOSEP % POSITIVITY BM FISH % POSITIVITY RB-1 PROBE ROBOSEP % POSITIVITY BM FISH % POSITIVITY TP53 PROBE ROBOSEP % POSITIVITY BM FISH % POSITIVITY 14

15 CKS1B PROBE ROBOSEP % POSITIVITY BM FISH % POSITIVITY PART VI: REPORTING ROBOSEP SAMPLE RESULTS New phrase codes: EPC ENRICHED PLASMA CELLS FROM BONE MARROW 27173: The enriched plasma cells used in this study are derived from bone marrow specimen using immunomagnetic cell separation technology, which increases FISH sensitivity for detecting cytogenetic abnormalities associated with myeloma. PART VII: VALIDATION STUDIES New procedure requires new analytic validation of all the myeloma panel probes using 20 negative control samples to establish a normal reference range or cutoff. Currently working on getting the data and eventually performing the statistical analysis to derive the cutoff value for each of the 4 probes currently in the MM panel. 15

16 ACKNOWLEDGEMENTS Thanks to Dr. Lu for bringing this technology to the lab Thanks to Denise for securing the RoboSep lease Thanks to Stem Cell for training and continued support ROMEO AND JULIET Thanks to the lab for adapting a new technology Thanks to the Technicians who set aside 175+ and counting samples for RoboSep processing Thanks to the XMatrx Team for their hard work towards integration Thanks to all RoboSep Team members: past (Aruna, Jun), present, and future! 16

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Multiple Myeloma Patient s Booklet

Multiple Myeloma Patient s Booklet 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Email : ncis@nuhs.edu.sg Website : www.ncis.com.sg LIKE US ON FACEBOOK www.facebook.com/ nationaluniversitycancerinstitutesingapore Multiple

More information

Enhance Sensitivity of FISH Analysis with Highly Purified Multiple Myeloma Cells Using RoboSep, the Fully Automated Cell Separator

Enhance Sensitivity of FISH Analysis with Highly Purified Multiple Myeloma Cells Using RoboSep, the Fully Automated Cell Separator Enhance Sensitivity of FISH Analysis with Highly Purified Multiple Myeloma Cells Using RoboSep, the Fully Automated Cell Separator Benoit Guilbault, PhD Field Applications Scientist t STEMCELL Technologies,

More information

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA Interesting Case Review Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA History 63 y/o male with h/o CLL for 10 years Presents with worsening renal function and hypercalcemia

More information

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE

More information

Hematology Morphology Critique

Hematology Morphology Critique Survey Slide: History: 60-year-old female presenting with pneumonia Further Laboratory Data: Hgb : 90 g/l RBC : 2.92 10 12 /L Hct : 0.25 L/L MCV : 87 fl MCH : 30.8 pg MCHC : 355 g/l RDW : 17.7 % WBC :

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

New diagnostic criteria for myeloma

New diagnostic criteria for myeloma New diagnostic criteria for myeloma Dr Guy Pratt Senior Lecturer/Honorary Consultant Haematologist University of Birmingham/Heart of England NHS Trust International Myeloma Working Group (IMWG) define

More information

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.

More information

DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES

DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES DELPHI 27 V 2016 CYTOMETRY STRATEGIES IN THE DIAGNOSIS OF HEMATOLOGICAL DISEASES CLAUDIO ORTOLANI UNIVERSITY OF URBINO - ITALY SUN TZU (544 b.c. 496 b.c) SUN TZU (544 b.c. 496 b.c.) THE ART OF CYTOMETRY

More information

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

Multiple Myeloma Workshop- Tandem 2014

Multiple Myeloma Workshop- Tandem 2014 Multiple Myeloma Workshop- Tandem 2014 1) Review of Plasma Cell Disorders Asymptomatic (smoldering) myeloma M-protein in serum at myeloma levels (>3g/dL); and/or 10% or more clonal plasma cells in bone

More information

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma.

Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. Multiple Myeloma. The term multiple myeloma is considered to be synonymous with myeloma, plasma cell myeloma, active and symptomatic myeloma. The intent is to positively identify patients with active or

More information

Things You Don t Want to Miss in Multiple Myeloma

Things You Don t Want to Miss in Multiple Myeloma Things You Don t Want to Miss in Multiple Myeloma Sreenivasa Chandana, MD, PhD Attending Hematologist and Medical Oncologist West Michigan Cancer Center Assistant Professor, Western Michigan University

More information

MULTIPLE MYELOMA 1 PLASMA CELL DISORDERS Multiple l Myeloma Monoclonal Gammopathy of Undetermined Significance (MGUS) Smoldering Multiple Myeloma (SMM) Solitary Plasmacytoma Waldenstrom s Macroglobulinemia

More information

TABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data

TABLE OF CONTENTS. Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data Instructions for Multiple Myeloma / Plasma Cell Leukemia Pre-HSCT Data (Form 2016) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Multiple Myeloma /

More information

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms

Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Clin Lab Med 27 (2007) 487 512 Flow Cytometric Evaluation of B-cell Lymphoid Neoplasms Fiona E. Craig, MD Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine,

More information

Minimal residual disease detection in Acute Myeloid Leukaemia on a Becton Dickinson flow cytometer

Minimal residual disease detection in Acute Myeloid Leukaemia on a Becton Dickinson flow cytometer Minimal residual disease detection in Acute Myeloid Leukaemia on a Becton Dickinson flow cytometer Purpose This procedure gives instruction on minimal residual disease (MRD) detection in patients with

More information

Multiple Myeloma and Colorectal Cancer

Multiple Myeloma and Colorectal Cancer Multiple Myeloma and Colorectal Cancer From Systems Immunology to Single Cells Leo Hansmann Mark M. Davis Lab Department of Microbiology&Immunology Stanford University Multiple Myeloma Monoclonal disease

More information

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic

Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells

More information

Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts

Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts Monoclonal Gammopathy of Undetermined Significance (MGUS) Facts Normal plasma cells (a type of white blood cell) produce antibodies (also known as immunoglobulins) which help fight infection. Each type

More information

Proteins. Protein Trivia. Optimizing electrophoresis

Proteins. Protein Trivia. Optimizing electrophoresis Proteins ELECTROPHORESIS Separation of a charged particle in an electric field Michael A. Pesce, Ph.D Department of Pathology New York-Presbyterian Hospital Columbia University Medical Center Rate of migration

More information

Extramedullary Plasmacytoma

Extramedullary Plasmacytoma Extramedullary Plasmacytoma Carole Fakhry MD MPH The Milton J. Dance, Jr. Head and Neck Center at GBMC HEAD AND NECK GRAND ROUNDS 9-5-2008, Baltimore, Maryland Plasmacytoma Monoclonal proliferation of

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Microarray-Based Gene Expression Profile Testing for Multiple File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_profile_testing_for_multiple_myeloma

More information

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology

MULTIPLE MYELOMA Review & Update for Primary Care. Dr. Joseph Mignone 21st Century Oncology MULTIPLE MYELOMA Review & Update for Primary Care Dr. Joseph Mignone 21st Century Oncology OVERVIEW Identify the diagnostic criteria for multiple myeloma Compare first & second line therapies, using data

More information

The Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo

The Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo The Effect of Myeloma Cells on Bone Metabolism is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo Deepika Kassen 1, Neil Rabin 1, Darren Lath 2, Peter Croucher 2 and

More information

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time

Why discuss CLL? Common: 40% of US leukaemia. approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Why discuss CLL? Common: 40% of US leukaemia approx 100 pa in SJH / MWHB 3 inpatients in SJH at any time Median age of dx is 65 (30s. Incurable, survival 2-202 20 years Require ongoing supportive care

More information

SOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008

SOUTHWEST ONCOLOGY GROUP CLINICAL RESEARCH ASSOCIATE (CRA) MANUAL. MYELOMA CHAPTER 10 REVISED: March 2008 Introduction This disease site includes the following three malignancies: multiple myeloma, amyloidosis, and waldenstrom's macroglobulinemia. See pages 4 and 5 for descriptions of the latter two diseases.

More information

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms Dr. Douaa Mohammed Sayed Small lymphocytic lymphoma/b-cell chronic lymphocytic leukemia BMB: nodular, interstitial, diffuse or a combination

More information

Mansour Al-Hiary MD *, Baheieh Al-Abbadi MD*, Nesreen Abu Hazeem MD*, Ali Swailmeen MD**, Najah Aldrous MD*, Nazmi Kamal MD* ABSTRACT

Mansour Al-Hiary MD *, Baheieh Al-Abbadi MD*, Nesreen Abu Hazeem MD*, Ali Swailmeen MD**, Najah Aldrous MD*, Nazmi Kamal MD* ABSTRACT Pattern of Serum Protein Electrophoresis Results in a Group of Patients with Plasma Cell Myeloma Confirmed by Bone Marrow Findings at King Hussein Medical Center Mansour Al-Hiary MD *, Baheieh Al-Abbadi

More information

Plasma cell dyscrasias Mark Drayson

Plasma cell dyscrasias Mark Drayson Plasma cell dyscrasias Mark Drayson Mortality statistics for England and Wales. Deaths attributed to multiple myeloma from 1988-1997 by age cohort as a percentage of total (21,257) deaths Deaths in age

More information

Investigation of B cell malignancies. Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital

Investigation of B cell malignancies. Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital Investigation of B cell malignancies Dr. Joanna Sheldon Protein Reference Unit St. George s s Hospital The B cell progression from «Pluripotent stem cell «Lymphoid committed stem cell «B lineage committed

More information

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

Whole Antibody and Free Light Chain Production by Plasma Cells

Whole Antibody and Free Light Chain Production by Plasma Cells MYELOMA Very Good ; Stringent or Complete Navigating the maze of Responses Parameswaran Hari Medical College of Wisconsin Milwaukee Increasing understanding of disease biology in the last few years Deeper

More information

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Aggressive lymphomas. Michael Crump Princess Margaret Hospital Aggressive lymphomas Michael Crump Princess Margaret Hospital What are the aggressive lymphomas? Diffuse large B cell Mediastinal large B cell Anaplastic large cell Burkitt lymphoma (transformed lymphoma:

More information

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH

Lymphoplasmacytic Lymphoma. Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Lymphoplasmacytic Lymphoma versus IGM Multiple Myeloma Hematology fellows conference 4/12/2013 Christina Fitzmaurice, MD, MPH Hematology consult patient 48 yo woman presents to ER with nonspecific complaints:

More information

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2008 WHO Classification of Lymphoid Neoplasms: Small B-Cell Neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone B-cell lymphoma Hairy

More information

NON SECRETORY MULTIPLE MYELOMA A CASE REPORT

NON SECRETORY MULTIPLE MYELOMA A CASE REPORT NON SECRETORY MULTIPLE MYELOMA A CASE REPORT Golwilkar A.,*Saluja R., Mehendale A. and Jalnapurkar N. Department of Histopathology, Golwilkar Metropolis Health Services (India) Pvt Ltd *Author for Correspondence

More information

Monitoring Residual Myeloma High-Resolution Serum/Urine Electrophoresis or Marrow Biopsy With Immunohistochemical Analysis?

Monitoring Residual Myeloma High-Resolution Serum/Urine Electrophoresis or Marrow Biopsy With Immunohistochemical Analysis? Hematopathology / Residual Disease Monitoring in Myeloma Monitoring Residual Myeloma High-Resolution Serum/Urine Electrophoresis or Marrow Biopsy With Immunohistochemical Analysis? Amanda D. Tatsas, MD,

More information

Understanding Serum Free Light Chain Assays

Understanding Serum Free Light Chain Assays Understanding Serum Free Light Chain Assays International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax:

More information

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.

More information

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand. 1 2 3 4 The FAB assigns a cut off of 30% blasts to define AML and relies predominantly on morphology and cytochemical stains (MPO, Sudan Black, and NSE which will be discussed later). Subtypes of AML follow

More information

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED?

WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? WHICH SAMPLES SHOULD BE SUBMITTED WHEN LYMPHOID NEOPLASIA IS SUSPECTED? Which test should be submitted? The answer to this depends on the clinical signs, and the diagnostic question you are asking. If

More information

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NATIONAL CANCER INSTITUTE. Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma NATIONAL CANCER INSTITUTE Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Basic Trial Information Phase Type Status Age Sponsor Protocol IDs Phase

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015 LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:

More information

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Diagnosis of HIV-1 Infection Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University Tests Used to Diagnose HIV-1 Infection HIV antibody (today s topic) HIV p24 antigen HIV DNA HIV

More information

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Cancer. 9p21.3 deletion. t(12;21) t(15;17) CANCER FISH PROBES INDIVIDUAL AND PANEL S Acute Lymphoblastic Leukemia (ALL) ALL FISH Panel (includes all probes below) 8010 LSI MYB/CEP6 LSI p16 (CDKN2A) LSI BCR/ABL with ASS LSI ETV6 (TEL)/AML1 (RUNX1)

More information

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology

More information

Workshop 14-16 February 2006

Workshop 14-16 February 2006 Theoretical and practical approaches of Hepatocyte primary culture Workshop 14-16 February 2006 Lecture (2) Disaggregation & purification of target cells Coarse organizer Dr. Abo bakr Mohamed Eltayeb General

More information

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative

More information

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D. Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates

More information

Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7

Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Continuing Medical Education Article Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias JNM, July 2012, Volume 53, Number 7 Authors Ronald C. Walker 1,2, Tracy L. Brown 3, Laurie B. Jones-Jackson

More information

A Focus on Multiple Myeloma

A Focus on Multiple Myeloma A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.

More information

Please note: Contact Coppe Laboratories at 262-574-0701 if archival plasma samples need to be tested.

Please note: Contact Coppe Laboratories at 262-574-0701 if archival plasma samples need to be tested. Collecting a Coppe Laboratories Sample The Coppe Laboratories Sample Kit contains: Test Request Form (TRF) Heparin tube Absorbent sheet Biohazard bag Foil pouch Label for blood tube Box Seal Instructions

More information

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

More information

Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma. Amitabha Mazumder, MD

Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma. Amitabha Mazumder, MD Use of free light chain analysis in the diagnosis, prognosis and therapy of multiple myeloma Amitabha Mazumder, MD Monoclonal Gammopathies Multiple Myeloma 18% Light Chain Dep Ds < 1% AL Amyloidosis 9%

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith, Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,

More information

DECIPHERING MY MYELOMA LAB RESULTS

DECIPHERING MY MYELOMA LAB RESULTS Myeloma DECIPHERING MY MYELOMA LAB RESULTS Do you understand your myeloma diagnosis and your myeloma lab results? This guide attempts to simplify the complex process of understanding your myeloma markers

More information

HER2 Testing in Breast Cancer

HER2 Testing in Breast Cancer HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor

More information

Carcinosarcoma of the Ovary

Carcinosarcoma of the Ovary Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year old

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

DECIPHERING MY MYELOMA LAB RESULTS

DECIPHERING MY MYELOMA LAB RESULTS DECIPHERING MY MYELOMA LAB RESULTS mpatient Myeloma Do you understand your myeloma diagnosis and your myeloma lab results? This guide attempts to simplify the complex process of understanding your myeloma

More information

Session 1 Plasma Cell Myeloma

Session 1 Plasma Cell Myeloma Session 1 Plasma Cell Myeloma Case 250 Plasma cell myeloma with other lymphoid malignancies or MBL Antonio Hernandez, MD, Ameripath Central Florida Society for Hematopathology European Association for

More information

for Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014

for Leucocyte Immunophenotyping Leukaemia Diagnosis Interpretation All Participants Date Issued: 08-September-2014 Closing Date: 26-September-2014 for Leucocyte Immunophenotyping Leukaemia Interpretation All Participants Participant: 4xxxx Trial No: 141502 Date Issued: 08-September-2014 Closing Date: 26-September-2014 Trial Comments This was an electronic

More information

HAEMATOLOGY LABORATORY

HAEMATOLOGY LABORATORY HAEMATOLOGY LABORATORY Head of Unit : Dr Raudhawati Osman Phone : +603-26155281 Email : raudhaosman@yahoo.com 1. INTRODUCTION The Haematology Unit, Department of Pathology, HKL provides tertiary diagnostic

More information

Preparation of Blood Films

Preparation of Blood Films Preparation of Blood Films Principle: Blood film enables us to evaluate WBC, RBC, and PLT morphology, also, allows us to perform differential WBC count, furthermore estimation of WBC and platelets counts

More information

Study of serum protein electrophoresis in suspected cases of Multiple Myeloma.

Study of serum protein electrophoresis in suspected cases of Multiple Myeloma. Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Study of serum protein electrophoresis in suspected cases of Multiple Myeloma. Dr. Dharmishtha N.

More information

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on examination. She also has fever, weight loss, and sweats. What

More information

Direct Antiglobulin Test (DAT)

Direct Antiglobulin Test (DAT) Exercise 8 Exercise 9 Direct Antiglobulin Test (DAT) Elution Study Task Aim Introduction To perform the DAT and elution procedure with correct interpretation of results. To perform with 100% accuracy the

More information

Something Old, Something New.

Something Old, Something New. Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan

More information

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation

More information

Pathology No: SHS-CASE No. Date of Procedure: Client Name Address

Pathology No: SHS-CASE No. Date of Procedure: Client Name Address TEL #: (650) 725-5604 FAX #: (650) 725-7409 Med. Rec. No.: Date of Procedure: Sex: A ge: Date Received: Date of Birth: Account No.: Physician(s): Client Name Address SPECIMEN SUBMITTED: LEFT PIC BONE MARROW,

More information

Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine.

Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine. Kharkov Regional Centre of Cardiovascular surgery V.N. Karazin Kharkov National University Department of Internal Medicine Multiple Myeloma Associate professor Abduyeva F.M., MD, PhD 2014 Definition Multiple

More information

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引

亞 東 紀 念 醫 院 Follicular Lymphoma 臨 床 指 引 前 言 : 惡 性 淋 巴 瘤 ( 或 簡 稱 淋 巴 癌 ) 乃 由 體 內 淋 巴 系 統 包 括 淋 巴 細 胞 淋 巴 管 淋 巴 腺 及 一 些 淋 巴 器 官 或 組 織 如 脾 臟 胸 腺 及 扁 桃 腺 等 所 長 出 的 惡 性 腫 瘤 依 腫 瘤 病 理 組 織 型 態 的 不 同 可 分 為 何 杰 金 氏 淋 巴 瘤 (Hodgkin s disease) 與 非 何 杰 金

More information

Phase II: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Neha Korde, MD, Clinical Investigator Ola Landgren, MD

Phase II: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Neha Korde, MD, Clinical Investigator Ola Landgren, MD Phase II: Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Neha Korde, MD, Clinical Investigator Ola Landgren, MD PhD, Principal Investigator Multiple Myeloma Section, NCI/NIH,

More information

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition

Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone. Relative Frequency of B-cell NHL. Diffuse Large B-cell Lymphoma Definition Diffuse Large B-cell Lymphoma, Burkitt Lymphoma and the Gray Zone L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Relative Frequency of B-cell NHL Diffuse large B-cell lymphoma 37 % Follicular lymphoma

More information

Haematological Features and Serum Protein Pattern on Electrophoresis of Multiple Myeloma in Sudanese Patients

Haematological Features and Serum Protein Pattern on Electrophoresis of Multiple Myeloma in Sudanese Patients Pyrex Journal of Clinical Pathology and Forensic Medicine Vol 1 (2) pp. 009-016 November, 2015 http:///pjcpfm Copyright 2015 Pyrex Journals Original Research Article Haematological Features and Serum Protein

More information

Disclosures for Elena Zamagni

Disclosures for Elena Zamagni Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients receiving upfront autologous stem-cell transplantation: a prospective study Zamagni E. 1, Nanni C. 2, Patriarca F. 3,

More information

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015 Welcome to Mayo Medical Laboratories Hot Topics. These presentations provide short discussion of current topics and may be helpful to you in your practice. Today our topic looks at hereditary platelet

More information

A Clinical Primer. for Managed Care Stakeholders

A Clinical Primer. for Managed Care Stakeholders reviews therapy Diagnosing, Staging, and Treating Multiple Myeloma: A Clinical Primer for Managed Care Stakeholders by Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders

More information

A Case of Aggressive Multiple Myeloma with Cleaved, Multilobated, and Monocytoid Nuclei, and No Serum Monoclonal Gammopathy

A Case of Aggressive Multiple Myeloma with Cleaved, Multilobated, and Monocytoid Nuclei, and No Serum Monoclonal Gammopathy Annals o f Clinical & Laboratory Science, vol. 30, no. 3, 2000 283 A Case of Aggressive Multiple Myeloma with Cleaved, Multilobated, and Monocytoid Nuclei, and No Serum Monoclonal Gammopathy Y. Albert

More information

Understanding Protein Electrophoresis

Understanding Protein Electrophoresis Understanding Protein Electrophoresis International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454

More information

Cytology of Lymph Nodes

Cytology of Lymph Nodes Indications Cytology of Lymph Nodes Lymph node enlargement That was easy Mary Anna Thrall Don Meuten Indications Lymph node enlargement Suspect metastasis Normal sized lymph nodes are Normal Do NOT aspirate

More information

Utility of flow cytometric κ and λ light chain analysis of peripheral blood

Utility of flow cytometric κ and λ light chain analysis of peripheral blood JBUON 2015; 20(5): 1322-1326 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Utility of flow cytometric κ and λ light chain analysis of peripheral

More information

Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD

Outline. Question 1. Question 2. What is Multiple Myeloma? Andrew Eisenberger, MD Outline A Disease Overview June 3, 2013 Andrew Eisenberger, MD Assistant Professor of Medicine Hematology/Oncology Columbia Presbyterian Medical Center Introduction Epidemiology/Risk Factors Clinical Features/Diagnostic

More information

CLL: Disease Course, Treatment, Diagnosis, and Biomarkers

CLL: Disease Course, Treatment, Diagnosis, and Biomarkers CLL: Disease Course, Treatment, Diagnosis, and Biomarkers Amy E. Hanlon Newell, Ph.D. Manager, Scientific Affairs Abbott Molecular Overview: Today s Take-away Understanding of: Cell phenotype and clinical

More information

Multiple Myeloma How to Evaluate Response To Treatment and Relapse

Multiple Myeloma How to Evaluate Response To Treatment and Relapse Multiple Myeloma How to Evaluate Response To Treatment and Relapse D R L. G AR D E R E T Saint Antoine Hospital, Paris Haematology Department 1 What is Multiple Myeloma? 4 Diagnostic Tools 8 Response to

More information

Table of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help?

Table of Contents Accelerate Your Research Introduction I. From the Real World to the Lab II. Research Challenges III. How Can Conversant Bio Help? Table of Contents Accelerate Your Research 2 Introduction 3 I. From the Real World to the Lab 4 A. Diagnosing Multiple Myeloma 4 1. Lab Tests 4 2. Bone Marrow Exams 6 3. Imaging Studies 7 B. Subtypes of

More information

Understanding Protein Electrophoresis

Understanding Protein Electrophoresis Understanding Protein Electrophoresis International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454

More information

Review Article The Genetic Architecture of Multiple Myeloma

Review Article The Genetic Architecture of Multiple Myeloma Advances in Hematology, Article ID 864058, 16 pages http://dx.doi.org/10.1155/2014/864058 Review Article The Genetic Architecture of Multiple Myeloma Steven M. Prideaux, Emma Conway O Brien, and Timothy

More information

Multiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee

Multiple Myeloma Making Sense of the Report Forms. Parameswaran Hari Medical College of Wisconsin Milwaukee Hodgkin CML MDS/Other Leuk CLL Neuroblastoma Multiple Myeloma Making Sense of the Report Forms Parameswaran Hari Medical College of Wisconsin Milwaukee Indications for Blood and Marrow Transplantation

More information

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY Torben Plesner, Henk Lokhorst, Peter Gimsing, Hareth Nahi, Steen Lisby, Paul Richardson

More information

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological

Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly

More information

Acute leukemias and myeloproliferative neoplasms

Acute leukemias and myeloproliferative neoplasms Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

Lab 02: Blood Cytology (20 points)

Lab 02: Blood Cytology (20 points) Pierce College Putman/Biol 242 Name: Lab 02: Blood Cytology (20 points) Reference: Marieb & Mitchell 9 th Ed: 29A (Activities 1, 2, 3, 4, 7); 10 th Ed: Exercise 29 (Activities 1, 2, 3, 4, 7). Pierce College

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Outline. Workup for metastatic breast cancer. Metastatic breast cancer Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30

More information